Literature DB >> 10933445

Treatment of chronic inflammatory demyelinating polyneuropathy.

G Comi1, L Roveri.   

Abstract

The management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the main topic of this review. A few comments will also be made about treatment of the demyelinating form of paraproteinaemic demyelinating polyneuropathy (PDN) and of multifocal motor neuropathy (MMN). The review briefly describes the main characteristics of these neuropathies, and examines case series and trials which evaluated the principal therapeutic strategies for CIDP, PDN and MMN, such as intravenous immunoglobulin (IVIg) therapy, steroid treatment, plasma exchange and immunosuppressor administration. Controlled trials demonstrated that IVIg, steroid treatment and plasma exchange are effective in CIDP. For PDN the therapeutic strategies are the same as for idiopathic CIDP, but usually the clinical response is poorer. For MMN, IVIg therapy is definitely the first choice treatment.

Entities:  

Mesh：

Year:  1998        PMID： 10933445     DOI： 10.1007/bf00713851

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  80 in total

1.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement.

Authors:  P A van Doorn; M Vermeulen; A Brand; P G Mulder; H F Busch
Journal:  Arch Neurol       Date:  1991-02

2.  Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance.

Authors:  N C Notermans; H M Lokhorst; H Franssen; Y Van der Graaf; L L Teunissen; F G Jennekens; L H Van den Berg; J H Wokke
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

3.  Prevalence of monoclonal protein in peripheral neuropathy.

Authors:  J J Kelly; R A Kyle; P C O'Brien; P J Dyck
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

4.  Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up.

Authors:  Y Nevo; A Pestronk; A J Kornberg; A M Connolly; W C Yee; I Iqbal; L K Shield
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

5.  Cyclosporin A therapy in paraprotein-associated neuropathy.

Authors:  J A Waterston; M M Brown; D A Ingram; M Swash
Journal:  Muscle Nerve       Date:  1992-04       Impact factor: 3.217

6.  Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide.

Authors:  G Blume; A Pestronk; L T Goodnough
Journal:  Neurology       Date:  1995-08       Impact factor: 9.910

7.  A syndrome of asymmetric limb weakness with motor conduction block.

Authors:  C Krarup; J D Stewart; A J Sumner; A Pestronk; S A Lipton
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

Review 8.  Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance.

Authors:  Z Simmons; M B Bromberg; E L Feldman; M Blaivas
Journal:  Muscle Nerve       Date:  1993-01       Impact factor: 3.217

9.  Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia.

Authors:  W H Sherman; M R Olarte; G McKiernan; K Sweeney; N Latov; A P Hays
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

10.  Plasma exchange in chronic inflammatory polyneuropathy: evidence suggestive of a pathogenic humoral factor.

Authors:  K V Toyka; R Augspach; H Wiethölter; U A Besinger; F Haneveld; U G Liebert; K Heininger; G Schwendemann; K Reiners; B Grabensee
Journal:  Muscle Nerve       Date:  1982 Jul-Aug       Impact factor: 3.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.